Placenta in Health and Disease - Grants, Research funding

We are grateful to the following Grant Agencies for funding our research:

Period

Grant title

Source

2023-2025 Cannabis use in pregnancy; effects on endocrine and immune functions of the placenta (GACR 23-07094S) GACR

2022-2025

National Institute for Neurological Research

EXCELES

2022-2025

Effects of gestational diabetes on placental inflammasome

AZV

2022-2024

Impact of maternal immune activation on serotonergic system in the fetoplacental unit and fetal, juvenile and adult neurodevelopment (GACR 22-08045S)

GACR

2022-2024

Use of cannabis in pregnancy; effect on placental functions

GAUK

2021-2023

Pregnancy disorders; effect on fetal development and programming

START

2021-2023

Pharmacotherapy in pregnancy; effect on monoamine homeostasis in the placenta

GAUK

2019-2022

Engineering a novel cell-based model for assessing materno-fetal drug transfer during pregnancy (OC-2019-019)

Swiss 3R Competence Centre

2020-2024

Placental tryptophan metabolism linking maternal inflammation and foetal neurodevelopmental disorders (AZV NU20-01-00264)

AZV

2020-2023

Antidepressants in pregnancy; effect on placental transport and metabolism of serotonin (GACR 20-13017S)

GACR

2019-2021

Pharmacotherapy in pregnancy; effect on monoamine homeostasis in the placenta

GAUK

2017-2019

In vitro, in situ and ex vivo study of interactions of novel antiviral agents with drug transporters; effect on their passage across the placenta (GACR 17-16169S)

GACR

2016-2018

Interactions of protein kinase inhibitors with drug transporters and biotransformation enzymes; role in overcoming resistance in anticancer therapy (GACR 16-26849S)

GACR

2012-2016

Transplacental pharmacokinetics of antiretroviral drugs; interactions with drug efflux transporters (P303/12/0850)

GACR

2012-2014

Study of interaction of cyclin-dependent kinase inhibitors with ABCB1 drug efflux transporter (700912 C 2012)

GAUK

2012-2014

Study of transplacental pharmacokinetics of antiretroviral drugs emtricitabine, tenofovir and tenofovir disoproxil fumarate; interactions with drug-efflux transporters (695912 C 2012)

GAUK

2010-2012

Localization and function of Organic Cation Transporter 3 (OTC3) in the Rat Placenta (114510 C 2009)

GAUK

2009-2011

Interactions of Breast Cancer Resistance Protein (BCRP/ABCG2) and Purine Cyclin-dependent Kinase Inhibitors In Vitro and In Situ (114909 C 2009)

GAUK

2007-2009

Role of efflux transporters in the placenta for fetus protection and detoxication (119007 C 2007)

GAUK

2007-2009

Regulation mechanisms of drug elimination during hepatic injury (116807 C 2007)

GAUK

2006-2008

Expression and function of BCRP in the placenta at different stages of gestation (103/2006 C)

GAUK

2006-2007

Expression and function of 11β-HSD2 in the placenta in vitro and in vivo (102/2006 C)

GAUK

2005-2008

In-vitro study of molecular-genetic cause of cell resistance against selected drugs (1A8696-4/2005)

IGA

2005-2007

Cytochrome P450 3A4 and multidrug resistance proteins MDR1 and MRP2 as main cause of drug interaction during elimination of drugs from organism (092/2005/C/LFHK)

GAUK

2005-2006

Study of interactions of antiepileptic drugs with efflux transporters (BCRP, MRP2 and P-glycoprotein) in vitro (94/2005/C/FaF)

GAUK

2005

RNA interference in transepithelial transport studies (753/2005)

FRVŠ

2004-2006

Investigation of drug efflux transporters using RNA interference and transfected cell lines (151/2004/C/FaF)

GAUK

2004

Building laboratories of molecular pharmacology (908/2004)

FRVŠ

2004

Visualization of placental membrane transporters using fluorescence microscopy (38p17)

AKTION

 

 

 

 

 

© Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 03 Hradec Králové, Czech Republic
Website information | Powered by Kentico